No Data
Private Companies Are Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Biggest Owners and Were Hit After Market Cap Dropped CN¥415m
Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?
Hendy Pharmaceuticals: third quarter report 2024
Hengdi Pharmaceutical (301211.SZ): The net income for the first three quarters was 74.6615 million yuan, a year-on-year decrease of 48.34%.
On October 27, Hengdi Pharmaceutical (301211.SZ) announced that in the first three quarters of 2024, it achieved revenue of 0.334 billion yuan, a decrease of 38.43% year-on-year; the net income attributable to shareholders of the listed company was 74.6615 million yuan, a decrease of 48.34%, with a basic earnings per share of 0.26 yuan.
Hengdi Pharmaceutical (301211.SZ) released its performance for the first three quarters, with a net income of 74.6615 million yuan, a year-on-year decrease of 48.34%.
Hengdi Pharmaceutical (301211.SZ) released the third quarter report for 2024, with revenue for the first three quarters reaching ...
Subdued Growth No Barrier To Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Price
No Data
